Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows that PI3K inhibition represents an intriguing mechanism for increasing CAR T-cell persistence that is easily reversible and CAR T-cell agnostic. The investigators hypothesize that PI3K inhibition with duvelisib would be safe, may provide effective prophylaxis against cytokine release syndrome (CRS), and may enhance the persistence and efficacy of CAR T-cells in the treatment of hematologic malignancies.

Study Overview

• Status: Recruiting
• Conditions: Acute Lymphocytic Leukemia; Non-hodgkin Lymphoma
• Intervention / Treatment: Drug: Duvelisib

• Study Type: Interventional
• Enrollment (Estimated): 43
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Armin Ghobadi, M.D.; Phone Number: 314-454-8304; Email: arminghobadi@wustl.edu

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Recruiting
      • Washington University School of Medicine
      • Sub-Investigator: John F DiPersio, M.D., Ph.D.
      • Sub-Investigator: Feng Gao, Ph.D.
      • Principal Investigator: Armin Ghobadi, M.D.
      • Contact: Armin Ghobadi, M.D.; Phone Number: 314-454-8304; Email: arminghobadi@wustl.edu
      • Sub-Investigator: Michael Slade, M.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Meets FDA-approved criteria for treatment of non-Hodgkin lymphoma (NHL) with axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi) or brexucabtagene autoleucel (Tecartus). Subjects receiving breuxacabtagene autoleucel for treatment of B-cell acute lymphoblastic leukemia (ALL) are not eligible.
• At least 18 years of age.
• The effects of duvelisib on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for at least 3 months after the last dose of duvelisib, as well as conform to institutional CAR T-cell guidelines. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for at least 3 months after the last dose of duvelisib.
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Receiving axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, or brexucabtagene autoleucel for the treatment of B-cell acute lymphoblastic leukemia.
• Known allergy or intolerance to duvelisib or another PI3K inhibitor. Previous treatment with duvelisib or other PI3K inhibitor is permitted unless therapy was discontinued due to toxicity or intolerance of therapy.
• Receiving therapy with a strong CYP3A inducer or inhibitor that cannot be discontinued during duvelisib therapy. Subjects receiving a strong CYP3A inducer or inhibitor at screening are eligible to participate if the drug can be discontinued the longest of the following time periods prior to initiation of duvelisib: 7 days (for strong CYP3A inhibitors), 14 days (for strong CYP3A inducers) or 4-5 half-lives (either inducer or inhibitor).
• Active CNS involvement by hematologic malignancy under treatment
• Evidence of uncontrolled infection of any origin (viral, bacterial, or fungal)
• Active bacterial, fungal or mycobacterial infection tuberculosis requiring treatment within the two years prior to study enrollment
• Known HIV infection, untreated hepatitis C or hepatitis B infection. Untreated hepatitis B is not an exclusion if hepatitis B is undetectable.
• Acute or chronic GVHD requiring systemic therapy
• Concurrent use of chronic systemic steroids or immunosuppressant medications
• Known history of immunologic/autoimmune disease affecting the CNS unrelated to diagnosis of hematologic malignancy under treatment
• Clinically significant pulmonary disease, defined as grade 2 or greater dyspnea or grade 2 or greater hypoxia
• Clinically significant cardiac disease, defined as unstable angina, acute myocardial infarction in the last 6 months, and NYHA class II or IV heart failure. Subjects with unstable arrhythmias that are not stable with medical management in 2 weeks prior to day -2 are also excluded.
• Clinically significant hepatic disease, defined as ALT, AST or alkaline phosphatase ≥ 3x ULN or total bilirubin > 1.5x ULN (unless related to Gilbert's or Meulengracht's syndrome). Subjects with a history of chronic liver disease, previous veno-occlusive disease, active alcohol abuse or history of alcohol abuse within the past 6 months are also excluded.
• Clinically significant renal disease, defined as calculated or measured creatinine clearance < 50 mL/min
• Currently breastfeeding or pregnant. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry.
• Inability to swallow and retain oral medication or prior surgery or GI dysfunction that may affect drug absorption (i.e. gastric bypass surgery, gastrectomy)
• Receipt of a prior investigational agent within 4 weeks before Day -3 or currently receiving any other investigational agents.
• Unable to receive prophylactic treatment for pneumocystis, HSV or VZV at screening
• Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of medication, attendance of study visits, elevated risk of complications or interference with interpretation of the study data
• A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease. Non-metastatic, non-melanoma skin cancers are not considered exclusionary.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A Dose Expansion Stage: Duvelisib; Patients in Cohort A will receive duvelisib from Day -2 to Day 28. The dose that will be given will be determined in the dose escalation stage (the maximum tolerated dose).; CAR T-cells will be given per standard of care.	Drug: Duvelisib; Patients should take duvelisib at approximately the same time every day, with or without food.
Experimental: Dose Escalation Stage: Duvelisib; Duvelisib is an oral medication taken on a once or twice daily basis on all dosing days. Doses being explored in this study are 15 mg BID (starting dose), 25 mg BID, and 15 mg QD. In the dose escalation stage, patients will receive duvelisib from Day -2 through Day 28.; CAR T-cells will be given per standard of care.	Drug: Duvelisib; Patients should take duvelisib at approximately the same time every day, with or without food.
Experimental: Cohort B Dose Expansion Stage: Duvelisib; Patients in Cohort B will receive duvelisib from Day -2 to Day 28 at the maximum tolerated dose (determined in dose expansion stage), followed by two weeks off therapy. This will be followed by 5 additional cycles of duvelisib for days 1-14 of 28 day cycles at the maximum tolerated dose.; CAR T-cells will be given per standard of care.	Drug: Duvelisib; Patients should take duvelisib at approximately the same time every day, with or without food.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Toxicity as measured by number of adverse events	Toxicity is graded using NCI CTCAE v 5.0	From start of treatment through 30 days after completion of treatment (up to day 60 for Cohort A and up to day 212 for Cohort B)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative incidence of cytokine release syndrome (CRS)	-Any and grade 3-4 per ASTCT criteria	By Day 28
Cumulative incidence of immune effector cell-associated neurotoxicity syndrome (ICANS)	-Any and grade 3-4 per ASCT criteria	By Day 28
Number of participants who receive anti-IL-6 agents for treatment of cytokine release syndrome (CRS)		Through completion of follow-up (estimated to be 6 months)
Number of participants who receive steroids for treatment of cytokine release syndrome (CRS)		Through completion of follow-up (estimated to be 6 months)
Best overall response rate	-Defined as proportion of subjects with complete response (CR) or partial response (PR) by Lugano criteria	At 1 month
Proportion of participants with partial response (PR) on Day 30 with improved response on Day 90		Day 90
Proportion of participants with partial response (PR) on Day 30 with improved response on Day 180		Day 180
Progression-free survival (PFS)		Through completion of follow-up (estimated to be 5 years)
Overall survival (OS)		Through completion of follow-up (estimated to be 5 years)
Number of participants with complete response (CR)		At 1 month
Number of participants with complete response (CR)		At 3 months
Number of participants with complete response (CR)		At 6 months
Best overall response rate	-Defined as proportion of subjects with complete response (CR) or partial response (PR) by Lugano criteria	At 3 months
Best overall response rate	-Defined as proportion of subjects with complete response (CR) or partial response (PR) by Lugano criteria	At 6 months

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Collaborators: National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital; SecuraBio
• Investigators: Principal Investigator: Armin Ghobadi, M.D., Washington University School of Medicine

Publications and helpful links

Helpful Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2022
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): May 31, 2030

Study Registration Dates

• First Submitted: September 3, 2021
• First Submitted That Met QC Criteria: September 3, 2021
• First Posted (Actual): September 14, 2021

Study Record Updates

• Last Update Posted (Actual): March 13, 2024
• Last Update Submitted That Met QC Criteria: March 12, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Hematologic Diseases; Leukemia, Lymphoid; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Other Study ID Numbers: 202111018; 5R35CA210084 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No